Therapeutic potential of mGluR5 targeting in Alzheimer's disease

Frontiers in Neuroscience

Volumn 9, Issue JUN, 2015, Pages

  Kumar, Anil ^a   Dhull, Dinesh K ^a   Mishra, Pooja S ^b  

^a PANJAB UNIVERSITY   (India)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Alzheimer's disease; Amyloid ; Glia; mGluR; MPEP; Neurodegeneration

Indexed keywords

EID: 84934757886     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2015.00215     Document Type: Short Survey

References (127)

1. Abdul-Ghani, M. A., Valiante, T. A., Carlen, P. L., and Pennefather, P. S. (1996). Metabotropic glutamate receptors coupled to IP3 production mediate inhibition of IAHP in rat dentate granule neurons. J. Neurophysiol. 76, 2691-2700.
2. Abeti, R., Abramov, A. Y., and Duchen, M. R. (2011). Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death. Brain 134(Pt 6), 1658-1672. doi: 10.1093/brain/awr104
3. Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K., and Watson, J. (1994). "Cell signalling," in Robertson's Molecular Biology of the Cell, eds B. Alberts, A. Johnson, J. Lewis, M. Raff, K. Roberts, and P. Walter (New York, NY: Galand Publishing), 721-782.
4. Alzheimer's Association. (2011). 2011 Alzheimer's disease facts and figures. Alzheimer's Dement. 7, 208-244. doi: 10.1016/j.jalz.2011.02.004
5. Aronica, E., Gorter, J. A., Rozemuller, A. J., Yankaya, B., and Troost, D. (2005). Interleukin-1 beta down-regulates the expression of metabotropic glutamate receptor 5 in cultured human astrocytes. J. Neuroimmunol. 160, 188-194. doi: 10.1016/j.jneuroim.2004.11.015
6. Balducci, C., Beeg, M., Stravalaci, M., Bastone, A., Sclip, A., Biasini, E., et al. (2010). Synthetic amyloid beta oligomers impair long-term memory independently of cellular prion protein. Proc. Natl. Acad. Sci. U.S.A. 107, 2295-2300. doi: 10.1073/pnas.0911829107
7. Berger, J. V., Dumont, A. O., Focant, M. C., Vergouts, M., Sternotte, A., Calas, A. G., et al. (2012). Opposite regulation of metabotropic glutamate receptor 3 and metabotropic glutamate receptor 5 by inflammatory stimuli in cultured microglia and astrocytes. Neuroscience 205, 29-38. doi: 10.1016/j.neuroscience.2011.12.044
8. Biber, K., Laurie, D. J., Berthele, A., Sommer, B., Tölle, T. R., Gebicke-Härter, P. J., et al. (1999). Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. J. Neurochem. 72, 1671-1680. doi: 10.1046/j.1471-4159.1999.721671.x
9. Bishop, G. M., and Robinson, S. R. (2004). Physiological roles of amyloid-beta and implications for its removal in Alzheimer's disease. Drugs Aging 21, 621-630. doi: 10.2165/00002512-200421100-00001
10. Block, M. L., Zecca, L., and Hong, J. S. (2007). Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8, 57-69. doi: 10.1038/nrn2038
11. Boucsein, C., Zacharias, R., Färber, K., Pavlovic, S., Hanisch, U. K., and Kettenmann, H. (2003). Purinergic receptors on microglial cells: functional expression in acute brain slices and modulation of microglial activation in vitro. Eur. J. Neurosci. 17, 2267-2276. doi: 10.1046/j.1460-9568.2003.02663.x
12. Braak, H., and Braak, E. (1991). Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1, 213-216. doi: 10.1111/j.1750-3639.1991.tb00661.x
13. Bruno, V., Battaglia, G., Copani, A., D'Onofrio, M., Di Iorio, P., De Blasi, A., et al. (2001). Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J. Cereb. Blood Flow Metab. 21, 1013-1033. doi: 10.1097/00004647-200109000-00001
14. Bruno, V., Ksiazek, I., Battaglia, G., Lukic, S., Leonhardt, T., Sauer, D., et al. (2000). Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology 39, 2223-2230. doi: 10.1016/S0028-3908(00)00079-4
15. Byrnes, K. R., Stoica, B., Loane, D. J., Riccio, A., Davis, M. I., and Faden, A. I. (2009). Metabotropic glutamate receptor 5 activation inhibits microglial associated inflammation and neurotoxicity. Glia 57, 550-560. doi: 10.1002/glia.20783
16. Casley, C. S., Lakics, V., Lee, H. G., Broad, L. M., Day, T. A., Cluett, T., et al. (2009). Up-regulation of astrocyte metabotropic glutamate receptor 5 by amyloid-β peptide. Brain Res. 1260, 65-75. doi: 10.1016/j.brainres.2008.12.082
17. Cherry, J. D., Olschowka, J. A., and O'Banion, M. K. (2014). Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J. Neuroinflammation 11:98. doi: 10.1186/1742-2094-11-98
18. Cirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., et al. (2003). In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J. Neurosci. 23, 8844-8853.
19. Collett, V. J., and Collingridge, G. L. (2004). Interactions between NMDA receptors and mGlu5 receptors expressed in HEK293 cells. Br. J. Pharmacol. 142, 991-1001. doi: 10.1038/sj.bjp.0705861
20. Conn, P. J., and Pin, J. P. (1997). Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37, 205-237. doi: 10.1146/annurev.pharmtox.37.1.205
21. D'Antoni, S., Berretta, A., Seminara, G., Longone, P., Giuffrida-Stella, A. M., Battaglia, G., et al. (2011). A prolonged pharmacological blockade of type-5 metabotropic glutamate receptors protects cultured spinal cord motor neurons against excitotoxic death. Neurobiol. Dis. 42, 252-264. doi: 10.1016/j.nbd.2011.01.013
22. Delaère, P., Duyckaerts, C., Masters, C., Beyreuther, K., Piette, F., and Hauw, J. J. (1990). Large amounts of neocortical beta A4 deposits without neuritic plaques nor tangles in a psychometrically assessed, non-demented person. Neurosci. Lett. 116, 87-93. doi: 10.1016/0304-3940(90)90391-L
23. Dewapriya, P., Li, Y. X., Himaya, S. W., Pangestuti, R., and Kim, S. K. (2013). Neoechinulin A suppresses amyloid-β oligomer-induced microglia activation and thereby protects PC-12 cells from inflammation-mediated toxicity. Neurotoxicology 35, 30-40. doi: 10.1016/j.neuro.2012.12.004
24. Dickson, D. W., Crystal, H. A., Bevona, C., Honer, W., Vincent, I., and Davies, P. (1995). Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging 16, 285-298; discussion 298-304. doi: 10.1016/0197-4580(95)00013-5
25. Doble, A. (1999). The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol. Ther. 81, 163-221. doi: 10.1016/S0163-7258(98)00042-4
26. Doherty, A. J., Palmer, M. J., Henley, J. M., Collingridge, G. L., and Jane, D. E. (1997). (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 36, 265-267. doi: 10.1016/S0028-3908(97)00001-4
27. Fan, M. M., and Raymond, L. A. (2007). N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol. 81, 272-293. doi: 10.1016/j.pneurobio.2006.11.003
28. Ferreira, S. T., and Klein, W. L. (2011). The Aβoligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol. Learn. Mem. 96, 529-543. doi: 10.1016/j.nlm.2011.08.003
29. Freir, D. B., Nicoll, A. J., Klyubin, I., Panico, S., McDonald, J. M., Risse, E., et al. (2011). Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat. Commun. 2, 336. doi: 10.1038/ncomms1341
30. Gasparini, F., Lingenhöhl, K., Stoehr, N., Flor, P. J., Heinrich, M., Vranesic, I., et al. (1999). 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38, 1493-1503. doi: 10.1016/S0028-3908(99)00082-9
31. Glabe, C. G. (2004). Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem. Sci. 29, 542-547. doi: 10.1016/j.tibs.2004.08.009
32. Glabe, C. G. (2008). Structural classification of toxic amyloid oligomers. J. Biol. Chem. 283, 29639-29643. doi: 10.1074/jbc.R800016200
33. Glenner, G. G., and Wong, C. W. (1984). Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890. doi: 10.1016/S0006-291X(84)80190-4
34. Hamilton, A., Esseltine, J. L., DeVries, R. A., Cregan, S. P., and Ferguson, S. S. (2014). Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease. Mol. Brain. 7:40. doi: 10.1186/1756-6606-7-40
35. Hamilton, A., Zamponi, G. W., and Ferguson, S. S. (2015). Glutamate receptors function as scaffolds for the regulation of β-amyloid and cellular prion protein signaling complexes. Mol. Brain. 8, 18. doi: 10.1186/s13041-015-0107-0
36. Hannan, A. J., Blakemore, C., Katsnelson, A., Vitalis, T., Huber, K. M., Bear, M., et al. (2001). PLC-beta1, activated via mGluRs, mediates activity-dependent differentiation in cerebral cortex. Nat. Neurosci. 4, 282-288. doi: 10.1038/85132
37. Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. doi: 10.1126/science.1072994
38. Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., et al. (2009). Systemic inflammation and disease progression in Alzheimer disease. Neurology 73, 768-774. doi: 10.1212/WNL.0b013e3181b6bb95
39. Homayoun, H., Stefani, M. R., Adams, B. W., Tamagan, G. D., and Moghaddam, B. (2004). Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 29, 1259-1269. doi: 10.1038/sj.npp.1300417
40. Hu, N. W., Nicoll, A. J., Zhang, D., Mably, A. J., O'Malley, T., Purro, S. A., et al. (2014). mGlu5 receptors and cellular prion protein mediate amyloid-β-facilitated synaptic long-term depression in vivo. Nat. Commun. 5, 3374. doi: 10.1038/ncomms4374
41. Jarrett, J. T., Berger, E. P., and Lansbury, P. T. Jr. (1993). The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693-4697. doi: 10.1021/bi00069a001
42. Joly, C., Gomeza, J., Brabet, I., Curry, K., Bockaert, J., and Pin, J. P. (1995). Molecular, functional, and pharmacological characterization of the metabotropic glutamate receptor type 5 splice variants: comparison with mGluR1. J. Neurosci. 15(5 Pt 2), 3970-3981.
43. Kerner, J. A., Standaert, D. G., Penney, J. B. Jr., Young, A. B., and Landwehrmeyer, G. B. (1997). Expression of group one metabotropic glutamate receptor subunit mRNAs in neurochemically identified neurons in the rat neostriatum, neocortex, and hippocampus. Brain Res. Mol. Brain Res. 48, 259-269. doi: 10.1016/S0169-328X(97)00102-2
44. Kessels, H. W., Nguyen, L. N., Nabavi, S., and Malinow, R. (2010). The prion protein as a receptor for amyloid-beta. Nature 466, E3-E4; discussion E4-E5. doi: 10.1038/nature09217
45. Kigerl, K. A., Gensel, J. C., Ankeny, D. P., Alexander, J. K., Donnelly, D. J., and Popovich, P. G. (2009). Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J. Neurosci. 29, 13435-13444. doi: 10.1523/JNEUROSCI.3257-09.2009
46. Kim, H. G., Moon, M., Choi, J. G., Park, G., Kim, A. J., Hur, J., et al. (2014). Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo. Neurotoxicology 40, 23-32. doi: 10.1016/j.neuro.2013.10.004
47. Kingston, A. E., O'Neill, M. J., Bond, A., Bruno, V., Battaglia, G., Nicoletti, F., et al. (1999). Neuroprotective actions of novel and potent ligands of group I and group II metabotropic glutamate receptors. Ann. N.Y. Acad. Sci. 890, 438-449. doi: 10.1111/j.1749-6632.1999.tb08022.x
48. Koller, M., and Urwyler, S. (2010). Novel N-methyl-D-aspartate receptor antagonists: a review of compounds patented since 2006. Expert Opin. Ther. Pat. 20, 1683-1702. doi: 10.1517/13543776.2010.533656
49. Kuchibhotla, K. V., Lattarulo, C. R., Hyman, B. T., and Bacskai, B. J. (2009). Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science 323, 1211-1215. doi: 10.1126/science.1169096
50. Kulijewicz-Nawrot, M., Verkhratsky, A., Chvátal, A., Syková, E., and Rodríguez, J. J. (2012). Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer's disease. J. Anat. 221, 252-262. doi: 10.1111/j.1469-7580.2012.01536.x
51. Lansbury, P. T. Jr. (1997). Structural neurology: are seeds at the root of neuronal degeneration? Neuron 19, 1151-1154. doi: 10.1016/S0896-6273(00)80406-7
52. Lauren, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., and Strittmatter, S. M. (2009). Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128-1132. doi: 10.1038/nature07761
53. Lee, J. M., Zipfel, G. J., and Choi, D. W. (1999). The changing landscape of ischaemic brain injury mechanisms. Nature 399(Suppl.), A7-A14. doi: 10.1038/399a007
54. Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., et al. (2006). A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357. doi: 10.1038/nature04533
55. Liao, B., Zhao, W., Beers, D. R., Henkel, J. S., and Appel, S. H. (2012). Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp. Neurol. 237, 147-152. doi: 10.1016/j.expneurol.2012.06.011
56. Lim, D., Iyer, A., Ronco, V., Grolla, A. A., Canonico, P. L., Aronica, E., et al. (2013). Amyloid beta deregulates astroglial mGluR5-mediated calcium signaling via calcineurin and Nf-kB. Glia 61, 1134-1145. doi: 10.1002/glia.22502
57. Lipton, S. A. (2007). Pathologically activated therapeutics for neuroprotection. Nat. Rev. Neurosci. 8, 803-808. doi: 10.1038/nrn2229
58. Littman, L., Tokar, C., Venkatraman, S., Roon, R. J., Koerner, J. F., Robinson, M. B., et al. (1999). Cyclobutane quisqualic acid analogues as selective mGluR5a metabotropic glutamic acid receptor ligands. J. Med. Chem. 42, 1639-1647. doi: 10.1021/jm9806897
59. Liu, F., Zhou, R., Yan, H., Yin, H., Wu, X., Tan, Y., et al. (2014). Metabotropic glutamate receptor 5 modulates calcium oscillation and innate immune response induced by lipopolysaccharide in microglial cell. Neuroscience 281C, 24-34. doi: 10.1016/j.neuroscience.2014.09.034
60. Liu, W., Tang, Y., and Feng, J. (2011). Cross talk between activation of microglia and astrocytes in pathological conditions in the central nervous system. Life Sci. 89, 141-146. doi: 10.1016/j.lfs.2011.05.011
61. López-Toledano, M. A., and Shelanski, M. L. (2004). Neurogenic effect of beta-amyloid peptide in the development of neural stem cells. J. Neurosci. 24, 5439-5444. doi: 10.1523/JNEUROSCI.0974-04.2004
62. Lujan, R., Nusser, Z., Roberts, J. D., Shigemoto, R., and Somogyi, P. (1996). Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus. Eur. J. Neurosci. 8, 1488-1500. doi: 10.1111/j.1460-9568.1996.tb01611.x
63. Malherbe, P., Kew, J. N., Richards, J. G., Knoflach, F., Kratzeisen, C., Zenner, M. T., et al. (2002). Identification and characterization of a novel splice variant of the metabotropic glutamate receptor 5 gene in human hippocampus and cerebellum. Brain Res. Mol. Brain Res. 109, 168-178. doi: 10.1016/S0169-328X(02)00557-0
64. Malinow, R. (2012). New developments on the role of NMDA receptors in Alzheimer's disease. Curr. Opin. Neurobiol. 22, 559-563. doi: 10.1016/j.conb.2011.09.001
65. Martin, B. K., Szekely, C., Brandt, J., Piantadosi, S., Breitner, J. C., Craft, S., et al. (2008). Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol. 65, 896-905. doi: 10.1001/archneur.2008.65.7.nct70006
66. Matta, J. A., Ashby, M. C., Sanz-Clemente, A., Roche, K. W., and Isaac, J. T. (2011). mGluR5 and NMDA receptors drive the experience- and activity-dependent NMDA receptor NR2B to NR2A subunit switch. Neuron 70, 339-351. doi: 10.1016/j.neuron.2011.02.045
67. McGeer, P. L., Itagaki, S., Tago, H., and McGeer, E. G. (1987). Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett. 79, 195-200. doi: 10.1016/0304-3940(87)90696-3
68. McGeer, P. L., and McGeer, E. G. (2007). NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol. Aging 28, 639-647. doi: 10.1016/j.neurobiolaging.2006.03.013
69. McGeer, P. L., and McGeer, E. G. (2015). Targeting microglia for the treatment of Alzheimer's disease. Expert Opin. Ther. Targets 19, 497-506. doi: 10.1517/14728222.2014.988707
70. Miguel-Hidalgo, J. J., Alvarez, X. A., Cacabelos, R., and Quack, G. (2002). Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res. 958, 210-221. doi: 10.1016/S0006-8993(02)03731-9
71. Minakami, R., Iida, K., Hirakawa, N., and Sugiyama, H. (1995). The expression of two splice variants of metabotropic glutamate receptor subtype 5 in the rat brain and neuronal cells during development. J. Neurochem. 65, 1536-1542. doi: 10.1046/j.1471-4159.1995.65041536.x
72. Moehle, M. S., and West, A. B. (2014). M1 and M2 immune activation in Parkinson's Disease: foe and ally? Neuroscience 2014, S0306-S4522(14)00975-0. doi: 10.1016/j.neuroscience.2014.11.018
73. Molnár, Z., Soós, K., Lengyel, I., Penke, B., Szegedi, V., and Budai, D. (2004). Enhancement of NMDA responses by beta-amyloid peptides in the hippocampus in vivo. Neuroreport 15, 1649-1652. doi: 10.1097/01.wnr.0000134471.06244.d2
74. Mosher, K. I., and Wyss-Coray, T. (2014). Microglial dysfunction in brain aging and Alzheimer's disease. Biochem. Pharmacol. 88, 594-604. doi: 10.1016/j.bcp.2014.01.008
75. Movsesyan, V. A., O'Leary, D. M., Fan, L., Bao, W., Mullins, P. G., Knoblach, S. M., et al. (2001). mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl) pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 296, 41-47.
76. Nakanishi, S. (1994). Metabotropic glutamate receptors: synaptic transmission, modulation, and plasticity. Neuron 13, 1031-1037. doi: 10.1016/0896-6273(94)90043-4
77. Nicoletti, F., Bruno, V., Copani, A., Casabona, G., and Knöpfel, T. (1996). Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci. 19, 267-271. doi: 10.1016/S0166-2236(96)20019-0
78. Nicoll, A. J., Panico, S., Freir, D. B., Wright, D., Terry, C., Risse, E., et al. (2013). Amyloid-beta nanotubes are associated with prion protein-dependent synaptotoxicity. Nat. Commun. 4, 2416. doi: 10.1038/ncomms3416
79. Oka, A., and Takashima, S. (1999). The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down's syndrome brains. Acta Neuropathol. 97, 275-278. doi: 10.1007/s004010050985
80. O'Leary, D. M., Movsesyan, V., Vicini, S., and Faden, A. I. (2000). Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br. J. Pharmacol. 131, 1429-1437. doi: 10.1038/sj.bjp.0703715
81. Orellana, J. A., Shoji, K. F., Abudara, V., Ezan, P., Amigou, E., Sáez, P. J., et al. (2011). Amyloid β-induced death in neurons involves glial and neuronal hemichannels. J. Neurosci. 31, 4962-4977. doi: 10.1523/JNEUROSCI.6417-10.2011
82. Overk, C. R., Cartier, A., Shaked, G., Rockenstein, E., Ubhi, K., Spencer, B., et al. (2014). Hippocampal neuronal cells that accumulate a-synuclein fragments are more vulnerable to Aβoligomer toxicity via mGluR5-implications for dementia with Lewy bodies. Mol. Neurodegener. 9:18. doi: 10.1186/1750-1326-9-18
83. Pallitto, M. M., and Murphy, R. M. (2001). A mathematical model of the kinetics of beta amyloid fibril growth from the denatured state. Biophys. J. 81, 1805-1822. doi: 10.1016/S0006-3495(01)75831-6
84. Paranjape, G. S., Gouwens, L. K., Osborn, D. C., and Nichols, M. R. (2012). Isolated amyloid-β(1-42) protofibrils, but not isolated fibrils, are robust stimulators of microglia. ACS Chem. Neurosci. 3, 302-311. doi: 10.1021/cn2001238
85. Pin, J. P., and Bockaert, J. (1995). Get receptive to metabotropic glutamate receptors. Curr. Opin. Neurobiol. 5, 342-349. doi: 10.1016/0959-4388(95)80047-6
86. Pin, J. P., and Duvoisin, R. (1995). The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34, 1-26. doi: 10.1016/0028-3908(94)00129-G
87. Pisani, A., Gubellini, P., Bonsi, P., Conquet, F., Picconi, B., Centonze, D., et al. (2001). Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 106, 579-587. doi: 10.1016/S0306-4522(01)00297-4
88. Plant, L. D., Boyle, J. P., Smith, I. F., Peers, C., and Pearson, H. A. (2003). The production of amyloid beta peptide is a critical requirement for the viability of central neurons. J. Neurosci. 23, 5531-5535.
89. Price, D. L., and Sisodia, S. S. (1998). Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 21, 479-505. doi: 10.1146/annurev.neuro.21.1.479
90. Pryor, N. E., Moss, M. A., and Hestekin, C. N. (2012). Unraveling the early events of amyloid-beta protein (A beta) aggregation: techniques for the determination of A beta aggregate size. Int. J. Mol. Sci. 13, 3038-3072. doi: 10.3390/ijms13033038
91. Puzzo, D., Privitera, L., Leznik, E., Fà, M., Staniszewski, A., Palmeri, A., et al. (2008). Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci. 28, 14537-14545. doi: 10.1523/JNEUROSCI.2692-08.2008
92. Rakic, P. (2003). Elusive radial glial cells: historical and evolutionary perspective. Glia 43, 19-32. doi: 10.1002/glia.10244
93. Rammes, G., Hasenjäger, A., Sroka-Saidi, K., Deussing, J. M., and Parsons, C. G. (2011). Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology 60, 982-990. doi: 10.1016/j.neuropharm.2011.01.051
94. Ransom, B. R., and Sontheimer, H. (1992). The neurophysiology of glial cells. J. Clin. Neurophysiol. 9, 224-251. doi: 10.1097/00004691-199204010-00005
95. Reddy, P. H., and McWeeney, S. (2006). Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models. Neurobiol. Aging 27, 1060-1077. doi: 10.1016/j.neurobiolaging.2005.04.014
96. Renner, M., Lacor, P. N., Velasco, P. T., Xu, J., Contractor, A., Klein, W. L., et al. (2010). Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 66, 739-754. doi: 10.1016/j.neuron.2010.04.029
97. Romano, C., Sesma, M. A., McDonald, C. T., O'Malley, K., Van den Pol, A. N., and Olney, J. W. (1995). Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J. Comp. Neurol. 355, 455-469. doi: 10.1002/cne.903550310
98. Romano, C., van den Pol, A. N., and O'Malley, K. L. (1996). Enhanced early developmental expression of the metabotropic glutamate receptor mGluR5 in rat brain: protein, mRNA splice variants, and regional distribution. J. Comp. Neurol. 367, 403-412.
99. Schiefer, J., Sprünken, A., Puls, C., Lüesse, H. G., Milkereit, A., Milkereit, E., et al. (2004). The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res. 1019, 246-254. doi: 10.1016/j.brainres.2004.06.005
100. Schoepp, D. D., Jane, D. E., and Monn, J. A. (1999). Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38, 1431-1476. doi: 10.1016/S0028-3908(99)00092-1
101. Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., and Sabatini, B. L. (2007). Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 2866-2875. doi: 10.1523/JNEUROSCI.4970-06.2007
102. Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., et al. (2008). Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842. doi: 10.1038/nm1782
103. Shigemoto, R., Kinoshita, A., Wada, E., Nomura, S., Ohishi, H., Takada, M., et al. (1997). Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J. Neurosci. 17, 7503-7522.
104. Shigemoto, R., Nomura, S., Ohishi, H., Sugihara, H., Nakanishi, S., and Mizuno, N. (1993). Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci. Lett. 163, 53-57. doi: 10.1016/0304-3940(93)90227-C
105. Shimohama, S., Tanino, H., Kawakami, N., Okamura, N., Kodama, H., Yamaguchi, T., et al. (2000). Activation of NADPH oxidase in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 273, 5-9. doi: 10.1006/bbrc.2000.2897
106. Shrivastava, A. N., Kowalewski, J. M., Renner, M., Bousset, L., Koulakoff, A., Melki, R., et al. (2013). β-amyloid and ATP-induced diffusional trapping of astrocyte and neuronal metabotropic glutamate type-5 receptors. Glia 61, 1673-1686. doi: 10.1002/glia.22548
107. Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., et al. (2005). Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 8, 1051-1058. doi: 10.1038/nn1503
108. Song, M. S., Rauw, G., Baker, G. B., and Kar, S. (2008). Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation. Eur. J. Neurosci. 28, 1989-2002. doi: 10.1111/j.1460-9568.2008.06498.x
109. Streit, W. J., and Xue, Q. S. (2014). Human CNS immune senescence and neurodegeneration. Curr. Opin. Immunol. 29, 93-96. doi: 10.1016/j.coi.2014.05.005
110. Tsacopoulos, M., and Magistretti, P. J. (1996). Metabolic coupling between glia and neurons. J. Neurosci. 16, 877-885.
111. Tu, J. C., Xiao, B., Naisbitt, S., Yuan, J. P., Petralia, R. S., Brakeman, P., et al. (1999). Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23, 583-592. doi: 10.1016/S0896-6273(00)80810-7
112. Um, J. W., Kaufman, A. C., Kostylev, M., Heiss, J. K., Stagi, M., Takahashi, H., et al. (2013). Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron 79, 887-902. doi: 10.1016/j.neuron.2013.06.036
113. Varney, M. A., Cosford, N. D., Jachec, C., Rao, S. P., Sacaan, A., Lin, F. F., et al. (1999). SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J. Pharmacol. Exp. Ther. 290, 170-181.
114. Verkhratsky, A., and Kettenmann, H. (1996). Calcium signalling in glial cells. Trends Neurosci. 19, 346-352. doi: 10.1016/0166-2236(96)10048-5
115. Verkhratsky, A., Olabarria, M., Noristani, H. N., Yeh, C. Y., and Rodriguez, J. J. (2010). Astrocytes in Alzheimer's disease. Neurotherapeutics 7, 399-412. doi: 10.1016/j.nurt.2010.05.017
116. Verkhratsky, A., Orkand, R. K., and Kettenmann, H. (1998). Glial calcium: homeostasis and signaling function. Physiol. Rev. 78, 99-141.
117. Vernon, A. C., Palmer, S., Datla, K. P., Zbarsky, V., Croucher, M. J., and Dexter, D. T. (2005). Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. Eur. J. Neurosci. 22, 1799-1806. doi: 10.1111/j.1460-9568.2005.04362.x
118. Walsh, D. M., and Selkoe, D. J. (2004). Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44, 181-193. doi: 10.1016/j.neuron.2004.09.010
119. Wang, Q., Walsh, D. M., Rowan, M. J., Selkoe, D. J., and Anwyl, R. (2004). Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci. 24, 3370-3378. doi: 10.1523/JNEUROSCI.1633-03.2004
120. Weksler, M. E., Szabo, P., Relkin, N. R., Reidenberg, M. M., Weksler, B. B., and Coppus, A. M. (2013). Alzheimer's disease and Down's syndrome: treating two paths to dementia. Autoimmun. Rev. 12, 670-673. doi: 10.1016/j.autrev.2012.10.013
121. Wilkinson, B. L., and Landreth, G. E. (2006). The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J. Neuroinflammation 3:30. doi: 10.1186/1742-2094-3-30
122. Won, H., Lee, H. R., Gee, H. Y., Mah, W., Kim, J. I., Lee, J., et al. (2012). Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 486, 261-265. doi: 10.1038/nature11208
123. Wu, J., Rush, A., Rowan, M. J., and Anwyl, R. (2001). NMDA receptor- and metabotropic glutamate receptor-dependent synaptic plasticity induced by high frequency stimulation in the rat dentate gyrus in vitro. J. Physiol. 533(Pt 3), 745-755. doi: 10.1111/j.1469-7793.2001.t01-1-00745.x
124. Yan, Y., and Wang, C. (2006). Abeta42 is more rigid than Abeta40 at the C terminus: implications for Abeta aggregation and toxicity. J. Mol. Biol. 364, 853-862. doi: 10.1016/j.jmb.2006.09.046
125. Yeh, C. Y., Vadhwana, B., Verkhratsky, A., and Rodríguez, J. J. (2011). Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer's disease. ASN Neuro. 3, 271-279. doi: 10.1042/AN20110025
126. Zabel, M. K., and Kirsch, W. M. (2013). From development to dysfunction: microglia and the complement cascade in CNS homeostasis. Ageing Res. Rev. 12, 749-756. doi: 10.1016/j.arr.2013.02.001
127. Zhong, J., Gerber, G., Kojiæ, L., and Randiæ, M. (2000). Dual modulation of excitatory synaptic transmission by agonists at group I metabotropic glutamate receptors in the rat spinal dorsal horn. Brain Res. 887, 359-377. doi: 10.1016/S0006-8993(00)03066-3